Related Experiment Video

Updated: Aug 16, 2026

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
10:24

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Published on: May 22, 2026

[Treatment of tuberculosis in children]

M Albertini1

  • 1Sevice de pédiatrie, CHU de Nice, hôpital de l'Archet-II, 06202 Nice cedex 03, France. albertini.m@chu-nice.fr

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|September 1, 2005
PubMed

Insights

Short-course tuberculosis treatment for children involves a 6-month regimen of isoniazid and rifampin, with pyrazinamide added for susceptible pulmonary cases. Complex cases, like HIV co-infection or drug resistance, require tailored, longer treatment durations.

Area of Science:

  • Pediatric infectious diseases
  • Mycobacterial infections
  • Pharmacotherapy

Context:

  • Tuberculosis (TB) treatment in children has advanced to shorter, standardized regimens.
  • Standard therapy involves isoniazid and rifampin for six months, with pyrazinamide for susceptible pulmonary TB.

Purpose:

  • To outline current pediatric tuberculosis treatment guidelines.
  • To address variations in treatment for different TB forms and patient populations.

Summary:

  • Pulmonary TB in children typically uses a 6-month regimen (isoniazid, rifampin, pyrazinamide).
  • Adult-type TB or high drug-resistance risk necessitates a fourth drug.
  • Extrapulmonary TB, especially disseminated disease and meningitis, requires 9-12 months of treatment.
  • HIV co-infection complicates treatment due to drug resistance and interactions.
  • Latent TB infection is treated with isoniazid and rifampin for 3 months.
  • Integrated care, including case detection and follow-up, is crucial for treatment completion.

Impact:

  • Provides a framework for effective pediatric TB management.
  • Highlights the need for individualized treatment strategies.
  • Emphasizes the importance of a holistic approach to combat childhood tuberculosis.

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories: